Literature DB >> 8608236

Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome.

R K Gherardi1, L Bélec, M Soubrier, D Malapert, M Zuber, J P Viard, L Intrator, J D Degos, F J Authier.   

Abstract

The polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes (POEMS) syndrome is a rare multisystem disorder of obscure pathogenesis associated with osteosclerotic myeloma. Circulating levels of proinflammatory cytokines (tumor necrosis factor-alpha (TNF-alpha) interleukin-1 beta [IL-1 beta], IL-2, IL-6, and interferon-gamma [IFN-gamma]), anti-inflammatory cytokines (transforming growth factor beta 1 [TGF beta 1], IL-4, IL-10, and IL-13), the cytokine carrier protein alpha 2 macroglobulin, IL-1 receptor antagonist (IL-1ra), soluble TNF receptors (sTNFr) p55 and p75, and soluble IL-6 receptor (sIL-6r) were determined in 15 patients with POEMS syndrome and 15 with multiple myeloma. Patients with POEMS syndrome had higher serum levels of IL-1 beta, TNF-alpha, and IL-6 and lower serum levels of TGF beta 1 than did patients with multiple myeloma. Serum levels of IL-2, IL-4, IL-10, IL-13, IFN-gamma, alpha 2 macroglobulin, and sIL-6r were similar in both groups. IL-1ra and sTNFrs were increased in POEMS syndrome, but out of proportion to the increase of IL-1 beta and TNF-alpha. Serial evaluations in 1 patient showed that proinflammatory cytokine serum levels paralleled disease activity assessed by platelet count and neurologic involvement. Our results suggest that the manifestations of POEMS syndrome might be regarded as the result of a marked activation of the proinflammatory cytokine network (IL-1 beta, IL-6, and TNF-alpha) associated with a weak or even decreased (TGF beta 1) antagonistic reaction insufficient to counteract the noxious effects of cytokines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608236

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  POEMS syndrome with severe neurological damage clinically recovered with lenalidomide.

Authors:  José F Tomás; Pilar Giraldo; Ramón Lecumberri; Sara Nistal
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 2.  Narrative review: the systemic capillary leak syndrome.

Authors:  Kirk M Druey; Philip R Greipp
Journal:  Ann Intern Med       Date:  2010-07-20       Impact factor: 25.391

3.  Localized Bilateral Juxtafoveal Photoreceptor Loss in POEMS: A New Association.

Authors:  Christopher K Hwang; Anton M Kolomeyer; Alexander J Brucker; Jessica I W Morgan; Charles W Nichols; Tomas S Aleman
Journal:  Retina       Date:  2017-07       Impact factor: 4.256

4.  The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis.

Authors:  Maryse Dagenais; Jeremy Dupaul-Chicoine; Todd Douglas; Claudia Champagne; Alexandre Morizot; Maya Saleh
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

5.  An atypical case of POEMS syndrome with IgG kappa M protein and end stage renal failure.

Authors:  Belda Dursun; Mehmet Artac; Halil Ibrahim Varan; Bahar Kilicarslan Akkaya; Gulten Karpuzoglu; Gultekin Suleymanlar
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

6.  Inhibitory effect and mechanism of mesenchymal stem cells on melanoma cells.

Authors:  J Zhang; L Hou; D Zhao; M Pan; Z Wang; H Hu; J He
Journal:  Clin Transl Oncol       Date:  2017-07-21       Impact factor: 3.405

7.  Volumetric modulated arc radiotherapy for limited osteosclerotic myeloma.

Authors:  Aurélie Robles; Antonin Levy; Coralie Moncharmont; Lamine Farid; Jean-Baptiste Guy; Nadia Malkoun; Lysian Cartier; Cyrus Chargari; Isabelle Guichard; Jean-Noël Talabard; Guy de Laroche; Nicolas Magné
Journal:  World J Radiol       Date:  2013-04-28

8.  Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.

Authors:  A Créange; L Bélec; B Clair; J D Degos; J C Raphaël; R K Gherardi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

Review 9.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

10.  Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis, and a potential target of immunoglobulin therapy?

Authors:  G Rostoker; J C Rymer; G Bagnard; M Petit-Phar; M Griuncelli; Y Pilatte
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.